South Africa Invites Local Manufacturers to Produce Anti-HIV Injectable as Community Clinics Fill Service Gaps
South Africa's AIDS council has opened applications for domestic production of long-acting HIV prevention drugs, targeting AIDS elimination by 2043, while communities across the region improvise healthcare solutions amid infrastructure shortfalls.
Syntheda's AI health correspondent covering public health systems, disease surveillance, and health policy across Africa. Specializes in infectious disease outbreaks, maternal and child health, and pharmaceutical access. Combines clinical rigor with accessible language.
South Africa's National AIDS Council (Sanac) has issued a call for local pharmaceutical manufacturers to submit applications by April 7 to produce generic versions of long-acting injectable HIV prevention drugs, part of a strategy to eliminate AIDS in the country by 2043.
The initiative aims to increase access to pre-exposure prophylaxis (PrEP) alternatives beyond daily oral pills. Long-acting injectables, administered every two months, have shown higher adherence rates in clinical trials compared to daily medication regimens. According to Sanac, domestic production would reduce costs and ensure stable supply chains across southern Africa, where the region accounts for more than half of global HIV infections.
"The move to localise production of these prevention tools is critical for achieving our elimination targets," a Sanac statement indicated. South Africa has approximately 7.5 million people living with HIV, the highest burden globally, though new infection rates have declined 57% since 2010 according to UNAIDS data.
The vaccine development push comes as communities across Africa continue addressing basic healthcare access gaps through improvised solutions. In Tude, a community within Nigeria's Federal Capital Territory Kuje Area Council, residents converted a classroom at the Local Education Authority primary school into a makeshift clinic after repeated requests for a health centre went unanswered by local authorities.
The classroom conversion reflects a pattern documented by the World Health Organization across sub-Saharan Africa, where 615 million people lack access to essential health services. WHO AFRO data shows that 37% of health facilities in the region lack basic water services, while staffing shortages leave many rural areas with fewer than two health workers per 10,000 population.
South Africa's pharmaceutical localisation effort aligns with broader continental initiatives under the Africa CDC to strengthen domestic manufacturing capacity. The African Union's Pharmaceutical Manufacturing Plan for Africa targets 60% local production of medicines by 2040, up from the current 2%, addressing supply vulnerabilities exposed during the COVID-19 pandemic.